SEATTLE --(BUSINESS WIRE)--Sep. 6, 2022-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced members of its management team will participate at
- Clinical data update from a first-in-human phase 1 study of ALPN-303 in healthy adults and plans for multiple patient-based studies beginning in 2023 - - First look at data from NEON-2 study of davoceticept in combination with pembrolizumab in advanced malignancies - - Disease experts to discuss
SEATTLE --(BUSINESS WIRE)--Aug. 18, 2022-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced that, in connection with the previously announced appointment
SEATTLE --(BUSINESS WIRE)--Aug. 11, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results
- Just – Evotec Biologics will apply its fully integrated technology platform to develop an optimized commercial process for ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases - HAMBURG, Germany & SEATTLE --(BUSINESS WIRE)--Aug.
SEATTLE --(BUSINESS WIRE)--Aug. 4, 2022-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at
- 20-year industry veteran with extensive global clinical development leadership experience in autoimmune and inflammatory diseases - SEATTLE --(BUSINESS WIRE)--Jul. 19, 2022-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing
SEATTLE --(BUSINESS WIRE)--Jun. 7, 2022-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of industry veteran Andrew S.
- ALPN-303 uniquely binds BAFF and APRIL with high affinity, differentiating from related inhibitors including wild-type TACI-Fc’s - - Ongoing phase 1 study demonstrates highly encouraging preliminary pharmacodynamic reductions in circulating immunoglobulins - SEATTLE --(BUSINESS WIRE)--Jun.
- ALPN-303 Novel Preclinical Data and Preliminary Phase 1 Data at EULAR – - Davoceticept (ALPN-202) Monotherapy Update and Trials in Progress Poster for Pembrolizumab Combination Study at ASCO - SEATTLE --(BUSINESS WIRE)--May 26, 2022-- Alpine Immune Sciences, Inc.
